C
36.56
1.27 (3.60%)
| Penutupan Terdahulu | 35.29 |
| Buka | 35.29 |
| Jumlah Dagangan | 782,013 |
| Purata Dagangan (3B) | 1,489,052 |
| Modal Pasaran | 3,852,390,400 |
| Harga / Pendapatan (P/E TTM) | 42.02 |
| Harga / Pendapatan (P/E Ke hadapan) | 76.92 |
| Harga / Jualan (P/S) | 5.61 |
| Harga / Buku (P/B) | 5.78 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 4 Nov 2025 |
| Margin Keuntungan | 19.55% |
| Margin Operasi (TTM) | 2.17% |
| EPS Cair (TTM) | 1.15 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 7.10% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | -26.00% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 1.00% |
| Nisbah Semasa (MRQ) | 3.07 |
| Aliran Tunai Operasi (OCF TTM) | 179.44 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 160.08 M |
| Pulangan Atas Aset (ROA TTM) | 9.18% |
| Pulangan Atas Ekuiti (ROE TTM) | 21.77% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Corcept Therapeutics Incorporat | Menurun | Menurun |
AISkor Stockmoo
2.0
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 5.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -2.5 |
| Purata | 2.00 |
|
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 11.49% |
| % Dimiliki oleh Institusi | 80.05% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Ingalls & Snyder Llc | 30 Sep 2025 | 7,697,984 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 105.00 (HC Wainwright & Co., 187.20%) | Beli |
| Median | 100.00 (173.52%) | |
| Rendah | 95.00 (UBS, 159.85%) | Pegang |
| Purata | 100.00 (173.52%) | |
| Jumlah | 2 Beli, 1 Pegang | |
| Harga Purata @ Panggilan | 51.41 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Canaccord Genuity | 23 Jan 2026 | 100.00 (173.52%) | Beli | 36.56 |
| 02 Jan 2026 | 99.00 (170.79%) | Beli | 38.20 | |
| HC Wainwright & Co. | 23 Jan 2026 | 105.00 (187.20%) | Beli | 36.56 |
| 02 Jan 2026 | 90.00 (146.17%) | Beli | 38.20 | |
| UBS | 16 Dec 2025 | 95.00 (159.85%) | Pegang | 81.12 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 31 Dec 2025 | Pengumuman | Corcept Receives Complete Response Letter for Relacorilant as a Treatment for Patients with Hypercortisolism |
| 04 Nov 2025 | Pengumuman | Corcept Therapeutics Announces Third Quarter Financial Results, Oncology Development Programs and Provides Corporate Update |
| 28 Oct 2025 | Pengumuman | Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |